With the rise of the BA.5 omicron subvariant, vaccine experts are urging high-risk individuals to get the COVID-19 booster now.

NEWYou can now listen to Fox News articles!

Five vaccine experts told Reuters that people at risk of severe disease who have not yet received a second COVID-19 booster should not wait for the next generation, Omicron-targeted vaccines, expected in the fall.

In many countries, including the United States, the BA.5 Omicron subvariant of the virus is increasing, but current vaccines continue to protect against hospitalization for severe illness and death.

And as the virus evolves, it’s unclear which version will become more common in the fall, or whether the new vaccines targeting BA.4/5 in the U.S. and BA.1 in Europe will be a good match.

A nurse prepares COVID-19 vaccines in Waterford, Michigan, U.S., April 8, 2022.
(REUTERS/Emily Elkonin)

“If you need a booster, get it now,” said the doctor. John Moore, professor of microbiology and immunology at Weill Cornell Medical College, wrote an editorial on the topic at hand.

In the United States, regulators have asked Pfizer Inc to develop vaccine boosters targeting BA.4 and BA.5 Omicron cousins, as well as the original virus, with partners BioNTech SE and Moderna Inc. They are expected to be ready by October.

Meanwhile, regulators in Europe have signaled they are ready to use an Omicron-based booster sooner rather than later, possibly targeting the BA.1 variant, which set a record number of infections last winter.


US regulators are hoping for an updated vaccine targeting the original strain and believe the Omicron variant offers greater protection than future variants and that a booster closest to the version in circulation is valuable.

Given the current outbreak and declining human immunity, experts told Reuters the best help for those at risk is a subordinate.

According to the US Centers for Disease Control and Prevention, only about 30% of people 50 and older who are eligible for the fourth vaccine dose have received the vaccine, compared to less than 10% of those aged 50-64. A fourth dose for people under 50 or without major risk factors has not been approved and has little support among scientific experts.

Moore said the evidence he’s seen, including at a US Food and Drug Administration meeting in June and since, suggests that the BA.4/5 booster has “no benefit” in terms of preventing infection compared to the original vaccine.

“The public should not look at these Omicron-based amplifiers as some kind of magic bullet that will change the face of the pandemic and solve all their problems. It will have minimal impact compared to the current amplifier we have,” he said.


Dr. Eric Topol, a genomics expert and director of the Scripps Institute for Translational Research in La Jolla, California, said that getting a second booster has a survival benefit over a single booster, which has been documented in five separate studies.

“Too many people are waiting when we have really good evidence,” he said.

Dr. According to Bob Wachter, head of the department of medicine at the University of California, San Francisco, it’s becoming increasingly clear that the longer it’s been since a person’s last donor, the more protected they are from infection and severe illness.

“There’s a ton of COVID around and it’s a highly contagious agent,” he said.

BA.5 has caused a wave of new cases worldwide and now accounts for nearly 82% of all coronavirus infections in the US.

Wachter does not believe that the reformulated BA.4/5 vaccines will be ready for release in two months. “It seems a little ambitious to me, even if they hit the timeline, it’s going to go to the highest risk groups first,” he said. “I think the average person would need three to four months.”


Pfizer told Reuters it has several million shots of the BA.4/5 vaccine it has produced.

As for Novavax Inc’s newly approved vaccine, the company has not yet applied for approval to use it as a booster.

While that’s great, the company’s boosters won’t be available anytime soon, according to Moore, who participated in the Novavax clinical trial. Novavax said it is developing the BA.4/5 amplifier and expects to have it ready by the fourth quarter.

Topol said: “Whatever happened in the pipe, there are a few months left.” “It’s a more virulent, pathogenic version of the virus, and it’s as smart as possible.”

Leave a Comment

Your email address will not be published.